Table 1 Characteristics of patients (n = 17) included in the final analysis and pretransplant and posttransplant details of their allogeneic hematopoietic stem cell transplantation (HSCT).
Characteristics of HSCT recipients | Total number | % |
|---|---|---|
Underlying disease | ||
Acute myeloid leukemia (AML) | 12 | 70.6 |
Acute lymphoblastic leukemia | 2 | 11.8 |
Lymphoma | 2 | 11.8 |
Aplastic anemia | 1 | 5.9 |
Conditioning regimen | ||
Myeloablative | 8 | 47.1 |
Reduced intensity | 9 | 52.9 |
Graft | ||
Peripheral blood stem cells | 16 | 94.1 |
Bone marrow | 1 | 5.9 |
Donor | ||
Related donor | 9 | 52.9 |
Unrelated donor | 8 | 47.1 |
HLA match | ||
Match | 16 | 94.1 |
Mismatch | 1 | 5.9 |
EBMT score32 | ||
Score ≤2 (low risk) | 6 | 35.3 |
Score >2 (high risk) | 11 | 64.7 |
Previous HSCT | ||
First HSCT | 14 | 82.4 |
Previous allogeneic HSCT | 1 | 5.9 |
Previous autologous HSCT | 2 | 11.8 |
Immunosuppressiona | ||
No immunosuppressive therapy | 6 | 35.3 |
Immunosuppressive therapyb | 11 | 64.7 |
Corticosteroids | 4 | 23.5 |
Cyclosporine | 7 | 41.2 |
Tacrolimus | 1 | 5.9 |
Sirolimus | 1 | 5.9 |
Severity of prior acute GvHD | ||
None | 13 | 76.5 |
I–II | 3 | 17.6 |
III–IV | 1 | 5.9 |
Chronic GvHD | ||
None | 5 | 29.4 |
I–II (mild to moderate) | 12 | 70.6 |
III–IV (severe) | 0 | 0 |
Affected organsb | ||
Skin | 4 | 23.5 |
Mucosa | 4 | 23.5 |
Liver | 9 | 52.9 |
Eyes | 2 | 11.8 |
Comorbidities prior vaccination | ||
Cardiovascular disease | 4 | 23.5 |
Diabetes mellitus | 2 | 11.8 |
Thrombosis or embolism | 3 | 17.6 |
